NYSEAMERICAN:BPMX Biopharmx (BPMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Biopharmx Stock (NYSEAMERICAN:BPMX) Get Biopharmx alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume336,508 shsAverage Volume2.15 million shsMarket Capitalization$111.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BiopharmX Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative topical and transmucosal therapies for dermatological and oral mucosal conditions. Headquartered in Princeton, New Jersey, the company applies proprietary formulations to address unmet needs in areas such as cutaneous warts, oral mucositis, herpes labialis and psoriasis. In addition to its prescription pipeline, BiopharmX markets OTC skincare products that include moisturizing creams, acne treatments and sun care formulations. The company’s lead product candidates include BPX-01, a mucoadhesive topical treatment for the prevention of oral mucositis in cancer patients; BPX-04, a topical gel for the treatment of cold sores (herpes labialis); BPX-07, a user-applied therapy for cutaneous warts; and BPX-02, a topical foam for mild-to-moderate plaque psoriasis. Several of these assets have completed Phase 2 clinical studies, and the company is pursuing regulatory interactions aimed at advancing pivotal trials and potential commercialization partnerships. BiopharmX’s research and development efforts leverage in-house formulation expertise alongside third-party manufacturing and clinical trial networks in the United States. Management has positioned the company to enter strategic alliances for broader geographic rollout upon regulatory approval, with a focus on markets that demonstrate high unmet need for non-systemic dermatological therapies. By combining a diversified product portfolio with a streamlined development model, BiopharmX aims to deliver differentiated treatments to patients and long-term value to shareholders.AI Generated. May Contain Errors. Read More Receive BPMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMX Stock News HeadlinesTMBRQ Trex Wind-down, Inc.April 19, 2024 | seekingalpha.comTrex Wind Down Inc (TMBRQ)April 17, 2024 | investing.comBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calling this 'the next major evolution in market infrastructure.' He's referring to a complete overhaul of America's financial system, and by law the entire $382 trillion U.S. financial system must migrate onto it by April 2027. BlackRock launched a fund on this new infrastructure and hit $2.8 billion in assets in three months. JPMorgan is running $2 billion a day through it. Goldman Sachs, Citi, Bank of America, and Wells Fargo have all announced full integration. The digital fuel powering this grid is up 374% over the last five years.June 22 at 1:00 AM | Awesomely, LLC (Ad)BioPharmX (BPMX) Stock Soars on Potential 'Breakthrough' Acne TreatmentJuly 8, 2023 | thestreet.comForm 424B5 Timber Pharmaceuticals, - StreetInsider.comOctober 3, 2022 | streetinsider.comOutlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - Yahoo FinanceSeptember 22, 2022 | finance.yahoo.comGlobal Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswireJuly 19, 2022 | globenewswire.comTimber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking AlphaJuly 17, 2022 | seekingalpha.comSee More Headlines BPMX Stock Analysis - Frequently Asked Questions How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) announced its earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $0.96. When did Biopharmx's stock split? Biopharmx's stock reverse split before market open on Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Biopharmx? Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Hawkins (HWKN), Novavax (NVAX) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings12/10/2019Today6/22/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CIKN/A Webwww.biopharmx.com Phone+1-650-8895020FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,278,000Free FloatN/AMarket Cap$111.86 million OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NYSEAMERICAN:BPMX) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredI’m shouting ‘Buy Now’ before this stock soarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredEvery time Musk needs a company, he buys it. He needs this one.Elon Musk doesn't rent - he buys. When he needed batteries, he built the Gigafactory. When he needed solar, he...Behind the Markets | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredElon’s big $266,000 per second purchaseElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Biopharmx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.